Targeting FLT3 for the Treatment of Leukemia

Seminars in Hematology

Volumn 45, Issue SUPPL.2, 2008, Pages

  Small, Donald ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ANTINEOPLASTIC AGENT; BAY 93006; CD135 ANTIGEN; CETUXIMAB; EB 10; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMATINIB; IMCEB 10; LESTAURTINIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SORAFINIB; STAT5 PROTEIN; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CANCER RELAPSE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG INHIBITION; GENE MUTATION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WILD TYPE;

ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 50049097137     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.07.007     Document Type: Article

References (34)

1. Small D., Levenstein M., Kim E., Carrow C., Amin S., Rockwell P., et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 91 (1994) 459-463
2. Carrow C., Levenstein M., Kaufmann S., Chen J., Amin S., Rockwell P., et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87 (1996) 1089-1096
3. Brown P., and Small D. FLT3 inhibitors: A paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer 40 (2004) 707-721
4. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (1996) 1911-1918
5. Gilliland D.G., and Griffin J.D. Role of FLT3 in leukemia. Curr Opin Hematol 9 (2002) 274-281
6. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439
7. Bao L., Wang X., Ryder J., Ji M., Chen Y., Chen H., et al. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: Subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol 77 (2006) 35-45
8. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
9. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97 (2001) 89-94
10. Rombouts W.J., Blokland I., Lowenberg B., and Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14 (2000) 675-683
11. Levis M., and Small D. FLT3: ITDoes matter in leukemia. Leukemia 17 (2003) 1738-1752
12. Meshinchi S., Alonzo T.A., Stirewalt D.L., Zwaan M., Zimmerman M., Reinhardt D., et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 108 (2006) 3654-3661
13. Bornhauser M., Illmer T., Schaich M., Soucek S., Ehninger G., and Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 109 (2007) 2264-2265
14. Gale R.E., Hills R., Kottaridis P.D., Srirangan S., Wheatley K., Burnett A.K., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): An analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106 (2005) 3658-3665
15. Levis M., Tse K.F., Smith B.D., Garrett E., and Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 98 (2001) 885-887
16. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
17. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 (2002) 3885-3891
18. Brown P., Meshinchi S., Levis M., Alonzo T.A., Gerbing R., Lange B., et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 104 (2004) 1841-1849
19. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
20. Knapper S., Burnett A.K., Littlewood T., Kell W.J., Agrawal S., Chopra R., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (2006) 3262-3270
21. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
22. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
23. Fiedler W., Serve H., Döhner H., Schwittay M., Ottmann O.G., O'Farrell A.M., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
24. DeAngelo D.J., Amrein P., Kovacsovics T.J., Klisovic R., Powell B.L., Cooper M., et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 108 (2006) 51a (abstr 158)
25. DeAngelo D.J., Stone R.M., Heaney M.L., Nimer S.D., Paquette R.L., Klisovic R.B., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108 (2006) 3674-3681
26. Levis M., Pham R., Smith B.D., and Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104 (2004) 1145-1150
27. Brown P., Levis M., McIntyre E., Griesemer M., and Small D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20 (2006) 1368-1376
28. Levis M., Smith D., Beran M., Baer M., Erba H.P., Cripe L., et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood 106 (2005) 121a (abstr 403)
29. Stone R.M., Fischer T., Paquette R., Schiller G., Schiffer C.A., Ehninger G., et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood 108 (2006) 50a (abstr 157)
30. Burnett A. AML17: A programme of treatment development in younger patients with acute myeloid leukaemia and high risk myelodysplastic syndrome. http://www.controlled-trials.com/cctspringview2/mrct/showTrial.html?mrid=274435&srch= Accessed February 25, 2008
31. Brown P., Levis M., McIntyre E., Griesemer M., and Small D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20 (2006) 1368-1376
32. Brown P., Levis M., Shurtleff S., Campana D., Downing J., and Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105 (2005) 812-820
33. Piloto O., Levis M., Huso D., Li Y., Li H., Wang M.N., et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res 65 (2005) 1514-1522
34. Piloto O., Nguyen B., Huso D., Kim K.T., Li Y., Witte L., et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res 66 (2006) 4843-4851